Clinical Impact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

In this comprehensive online program for pathologists and medical oncologists gain expert guidance on optimal biomarker testing to identify patients with RET-dependent NSCLC and thyroid cancers and on integration of RET inhibitors into clinical practice. Read expert-authored commentaries listen to a podcast or watch an on-demand Webcast archived from a CCO live Webinar followed by downloading the associated slideset.

Share

Program Content

Activities

NSCLC and Thyroid Cancer: <i>RET</i>
RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: February 12, 2021

Expires: February 11, 2022

<em>RET</em>-Altered Cancers
Multidisciplinary Perspectives Informing Optimal Treatment of RET-Altered Lung and Thyroid Cancer
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2021

Expires: April 07, 2022

Activities

<i>RET</i> Biomarker Testing
Testing for RET Gene Alterations in Lung and Thyroid Cancers: A Resource for Clinicians
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2021

Expires: January 20, 2022

RET Inhibitor Efficacy
Efficacy of Selective RET Inhibitors in RET-Driven NSCLC and Thyroid Cancer: A Resource for Clinicians
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2021

Expires: January 20, 2022

RET Inhibitor Indications and Safety
A Clinician’s Guide to Selective RET Inhibitors for Patients With RET-Altered Lung and Thyroid Cancers: Indications, Dosing, and Adverse Events
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2021

Expires: January 20, 2022

Activities

<i>RET</i>-Driven NSCLC and Thyroid Cancer
RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2021

Expires: January 20, 2022

RET Inhibition: Lung Cancer
The Latest Evidence on Selective RET Inhibition in Advanced RET Fusion–Positive NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 16, 2021

Expires: March 15, 2022

RET Inhibition: Thyroid Cancer
Selective RET Inhibition in Metastatic RET-Mutant Medullary Thyroid Cancer and RET Fusion–Positive Differentiated Thyroid Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 16, 2021

Expires: March 15, 2022

Testing for <i>RET</i> Alterations
RET in Oncogenesis and Evidence-Based Testing Strategies to Detect RET Fusions and Mutations
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 16, 2021

Expires: March 15, 2022

<i>EP: RET+</i> NSCLC and Thyroid Cancer
ExpressPoints: Expert Guidance for Improving Outcomes in RET-Driven NSCLC and Thyroid Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2021

Expires: January 28, 2022

<i>EP</i>: RET Perspectives
ExpressPoints: Multidisciplinary Perspectives Informing Optimal Treatment of RET-Altered Lung and Thyroid Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2021

Expires: April 12, 2022

Activities

<em>RET</em> Fusion–Positive NSCLC
Clinical Considerations for RET Fusion–Positive NSCLC
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: September 17, 2020

Expires: September 16, 2021

<em>Podcast Pearls</em>: <i>RET</i>+ NSCLC
Podcast Pearls: Clinical Considerations for RET Fusion–Positive NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 17, 2020

Expires: September 16, 2021

Activities

FAQ: Selective RET Inhibition
Expert Answers to Frequently Asked Questions About Selective RET Inhibition in RET-Driven Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2021

Expires: May 10, 2022

Precision Medicine: Lung and Thyroid
Talking With Your Patients About Precision Medicine for Lung and Thyroid Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 23, 2021

Expires: February 22, 2022

Case: <i>RET</i> Fusion–Positive NSCLC
How I Am Using Selective RET Inhibitors in Lung Cancer Care Today
Case Challenge
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 02, 2020

Expires: September 01, 2021

<i>RET</i>-Altered Thyroid Cancer
Targeting RET in Advanced Thyroid Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 04, 2020

Expires: November 03, 2021

Faculty

cover img faculity

Dara L. Aisner, MD, PhD

Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

cover img faculity

Joshua Bauml, MD

Instructor, Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Staff Physician
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

cover img faculity

Marcia Brose, MD, PhD, FASCO

Professor
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Jefferson Northeast
Philadelphia, Pennsylvania

cover img faculity

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Professor
Coordinator of Oncology Concentration

Yale University School of Nursing
Oncology Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

cover img faculity

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

cover img faculity

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

cover img faculity

Laura J. Tafe, MD

Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire

cover img faculity

Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly